Appointment of Piper Jaffray as Nominated Advisor and Broker

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Dec 01, 2009

Porton Down, UK, 1 December 2009 - GW Pharmaceuticals plc (AIM: GWP) is pleased to announce the appointment, with immediate effect, of Piper Jaffray Ltd as Nominated Advisor and broker to the Company.

For further information please contact:

GW Pharmacueticals +44 (0)20  7831 3113
Dr. Geoffrey Guy, Executive Chairman / Justin Gover, Managing Director

Piper Jaffray Ltd +44 (0)20 3142 8700
Neil Mackison / Rupert Winckler

Financial Dynamics +44 (0)20 7831 3113
Ben Atwell / John Dineen

Notes to Editors:

About GW Pharmaceuticals

GW Pharmaceuticals was founded in 1998 and listed on the AIM, a market of the London Stock Exchange, in June 2001. Operating under license from the UK Home Office, the company researches and develops cannabinoid pharmaceutical products for patients who suffer from a range of serious ailments, in particular multiple sclerosis and cancer pain. GW has assembled a large in-house scientific team with expertise in cannabinoid science as well as experience in the development of both plant-based prescription pharmaceutical products and medicines containing controlled substances. GW occupies a world leading position in cannabinoids and has developed an extensive international network of the most prominent scientists in the field. For more information, visit

Recent News